このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Integral Diagnostics マネジメント

マネジメント基準チェック /24

Integral Diagnostics'の CEO はIan Kadishで、 May2017年に任命され、の在任期間は 7.25年です。の年間総報酬はA$ 1.10Mで、 71.2%給与と28.8%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.24%を直接所有しており、その価値はA$ 1.39M 。経営陣と取締役会の平均在任期間はそれぞれ3.9年と2.1年です。

主要情報

Ian Kadish

最高経営責任者

AU$1.2m

報酬総額

CEO給与比率	66.3%
CEO在任期間	7.3yrs
CEOの所有権	0.3%
経営陣の平均在職期間	4.8yrs
取締役会の平均在任期間	2.2yrs

経営陣の近況

Recent updates

CEO報酬分析

Integral Diagnostics の収益と比較して、Ian Kadish の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Jun 30 2024	AU$1m	AU$825k	-AU$61m
Mar 31 2024	n/a	n/a	-AU$59m
Dec 31 2023	n/a	n/a	-AU$58m
Sep 30 2023	n/a	n/a	-AU$16m
Jun 30 2023	AU$1m	AU$794k	AU$25m
Mar 31 2023	n/a	n/a	AU$23m
Dec 31 2022	n/a	n/a	AU$21m
Sep 30 2022	n/a	n/a	AU$18m
Jun 30 2022	n/a	AU$781k	AU$15m
Mar 31 2022	n/a	n/a	AU$18m
Dec 31 2021	n/a	n/a	AU$22m
Sep 30 2021	n/a	n/a	AU$26m
Jun 30 2021	AU$2m	AU$736k	AU$31m
Mar 31 2021	n/a	n/a	AU$32m
Dec 31 2020	n/a	n/a	AU$32m
Sep 30 2020	n/a	n/a	AU$28m
Jun 30 2020	AU$1m	AU$635k	AU$23m
Mar 31 2020	n/a	n/a	AU$22m
Dec 31 2019	n/a	n/a	AU$21m
Sep 30 2019	n/a	n/a	AU$21m
Jun 30 2019	AU$876k	AU$549k	AU$21m
Mar 31 2019	n/a	n/a	AU$19m
Dec 31 2018	n/a	n/a	AU$17m
Sep 30 2018	n/a	n/a	AU$16m
Jun 30 2018	AU$711k	AU$489k	AU$15m

報酬と市場: Ianの総報酬 ($USD 739.36K ) は、 Australian市場 ($USD 876.19K ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Ianの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Ian Kadish (61 yo)

7.3yrs

在職期間

AU$1,243,752

報酬

Dr. Ian Kadish, MBBCh, MBA, has been the Chief Executive Officer, Managing Director and Director at Integral Diagnostics Limited since May 22, 2017. Dr. Kadish serves as Independent Non-Executive Director...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Ian Kadish	CEO, MD & Director	7.3yrs	AU$1.24m	0.25% A$ 1.8m
Jacqueline Milne	Executive Director	4.8yrs	AU$1.15m	0.011% A$ 75.3k
Scott Paterson	Chief Financial Officer	less than a year	データなし	データなし
Julian Gully	Chief Information Officer	5yrs	データなし	データなし
John Merity	Interim Company Secretary	less than a year	データなし	データなし

4.8yrs

平均在職期間

経験豊富な経営陣: IDXの経営陣は経験豊富であると考えられます ( 3.9年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Ian Kadish	CEO, MD & Director	no data	AU$1.24m	0.25% A$ 1.8m
Jacqueline Milne	Executive Director	4.8yrs	AU$1.15m	0.011% A$ 75.3k
Raelene Murphy	Independent Non-Executive Director	6.9yrs	AU$140.53k	0.013% A$ 92.5k
Andrew Fay	Independent Non-Executive Director	2.2yrs	AU$137.50k	0.036% A$ 254.2k
Ingrid Player	Independent Non-Executive Director	1.1yrs	AU$111.22k	0.015% A$ 104.6k
James Hall	Independent Non-Executive Chairman	less than a year	AU$168.37k	0.065% A$ 453.6k

2.2yrs

平均在職期間

59yo

平均年齢

経験豊富なボード: IDXの取締役会は経験豊富ではない ( 2.1年の平均在任期間) ため、新しい取締役会が必要であると考えられます。

Integral Diagnostics マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

IDX™ Announces Appointment of Scott Paterson as Worldwide CFO

Integral Diagnostics Limited, Annual General Meeting, Nov 01, 2024

Integral Diagnostics Limited Announces Change of Company Secretary

Independent Non-Executive Director recently bought AU$258k worth of stock

Integral Diagnostics Limited Announces Resignation of Helen Kurincic as Director Effective 29 November 2023

Integral Diagnostics Limited Appoints Toby Hall as Director

Recent updates

Full year 2024 earnings released: AU$0.26 loss per share (vs AU$0.11 profit in FY 2023)

Integral Diagnostics Limited (ASX:IDX) agreed to acquire Capitol Health Limited (ASX:CAJ) for approximately AUD 350 million.

Integral Diagnostics Limited (ASX:IDX) agreed to acquire Capitol Health Limited (ASX:CAJ) for approximately AUD 350 million.

First half dividend of AU$0.025 announced

First half 2024 earnings released: AU$0.29 loss per share (vs AU$0.069 profit in 1H 2023)

IDX™ Announces Appointment of Scott Paterson as Worldwide CFO

Integral Diagnostics Limited, Annual General Meeting, Nov 01, 2024

Integral Diagnostics Limited Announces Change of Company Secretary

Independent Non-Executive Director recently bought AU$258k worth of stock

Integral Diagnostics Limited Announces Resignation of Helen Kurincic as Director Effective 29 November 2023

Investor sentiment deteriorates as stock falls 27%

Integral Diagnostics Limited Appoints Toby Hall as Director

Integral Diagnostics Limited Declares Fully Franked Final Dividend for the Six Months Ended June 30, 2023, Payable on October 04, 2023

Full year 2023 earnings released: EPS: AU$0.11 (vs AU$0.07 in FY 2022)

Integral Diagnostics Limited Declares Fully Franked Final Dividend, Payable on October 04, 2023

Integral Diagnostics Limited Announces Board Changes

Upcoming dividend of AU$0.025 per share at 2.0% yield

First half 2023 earnings released: EPS: AU$0.069 (vs AU$0.051 in 1H 2022)

Integral Diagnostics Limited Announces Ordinary Dividend for the Six Months Ended December 31, 2022, Payable on April 4, 2023

Now 21% undervalued

Integral Diagnostics Limited to Report First Half, 2023 Results on Feb 17, 2023

Integral Diagnostics Limited to Report Fiscal Year 2023 Results on Aug 28, 2023

Independent Non-Executive Director recently bought AU$114k worth of stock

Integral Diagnostics Limited Declares Fully Franked Final Dividend for the Year Ended June 30, 2022, Payable on October 5, 2022

Full year 2022 earnings released

Investor sentiment improved over the past week

Integral Diagnostics Limited Announces Appointment of Andrew Fay as an Independent Non-Executive Director

Now 21% undervalued after recent price drop

Healius Reportedly Keeps Watching Brief on Integral Diagnostics

Integral Diagnostics Limited (ASX:IDX) ) agreed to acquire Exact Radiology Pty Ltd for NZD 33.3 million.

Integral Diagnostics Limited (ASX:IDX) agreed to acquire Exact Radiology Pty Ltd for approximately AUD 39 million.

Executive Director recently bought AU$70k worth of stock

First half 2022 earnings: EPS in line with analyst expectations despite revenue beat

Integral Diagnostics Limited Announces the Distribution for the Six Months Ended December 31, 2021, Payable on April 4, 2022

Investor sentiment deteriorated over the past week

Full year 2021 earnings released: EPS AU$0.16 (vs AU$0.12 in FY 2020)

Executive Director has left the company

First half 2021 earnings released: EPS AU$0.10 (vs AU$0.062 in 1H 2020)

Revenue beats expectations

Integral Diagnostics Limited Announces Retirement of Dr. Chien Ho as Executive Director, Effective on March 1, 2021

Integral Diagnostics Limited to Report First Half, 2021 Results on Feb 22, 2021

New 90-day high: AU$4.48

New 90-day high: AU$4.42

Executive Director recently sold AU$266k worth of stock

Executive Director recently sold AU$123k worth of stock

Integral Diagnostics Limited (ASX:IDX) agreed to acquire Ascot Radiology Limited for NZD 54 million.

Integral Diagnostics Limited (ASX:IDX) completed the acquisition of Ascot Radiology Limited.

New 90-day high - AU$4.30

Earnings released

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

取締役

平均在職期間

平均年齢

マネジメント基準チェック /24